This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

Richard J. Meelia net worth and biography

Richard Meelia Biography and Net Worth

Director of Haemonetics

Mr. Richard J. Meelia is an Independent Director at ConforMIS, Inc., a Chairman at Haemonetics Corp. and a Manager at Meelia Ventures LLC. He is on the Board of Directors at ConforMIS, Inc., Mallinckrodt LLC, Por Christo, St. Francis House, Triangle, Inc., Tufts Medical Center, Inc., Elms College and St. Anselm College. Mr. Meelia was previously employed as a Chairman by Apollo Endosurgery, Inc., a Chairman by Covidien Plc, a President by Tyco Healthcare Group LP, a President & Chief Executive Officer by Tyco Healthcare Ltd., a Group President by Kendall Healthcare Products, a President by InfusAID, Inc., a Vice President-Sales & Marketing by American Hospital Supply Corp., a Chairman by Apollo Endosurgery, Inc. /Old/, a President by Covidien Holding, Inc., a Chairman by EmployAbility, Inc., an Associate by Kairos Partners, and a Principal by The Kendall Co. He also served on the board at Somanetics Corp. and Aspect Medical Systems, Inc. He received his undergraduate degree from St. Anselm College and an MBA from Boston College.

What is Richard J. Meelia's net worth?: The estimated net worth of Richard J. Meelia is at least $446,839.70 as of July 25th, 2017. Mr. Meelia owns 5,098 shares of Haemonetics stock worth more than $446,840 as of April 26th. This net worth estimate does not reflect any other investments that Mr. Meelia may own. Learn More about Richard J. Meelia's net worth.
How do I contact Richard J. Meelia?: The corporate mailing address for Mr. Meelia and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected]. Learn More on Richard J. Meelia's contact information.
Has Richard J. Meelia been buying or selling shares of Haemonetics?: Richard J. Meelia has not been actively trading shares of Haemonetics during the past quarter. Learn More on Richard J. Meelia's trading history.
Who are Haemonetics' active insiders?: Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.
Are insiders buying or selling shares of Haemonetics?: During the last twelve months, insiders at the medical instruments supplier sold shares 4 times. They sold a total of 9,765 shares worth more than $863,630.52. The most recent insider tranaction occured on September, 12th when insider Stewart W Strong sold 228 shares worth more than $20,668.20. Insiders at Haemonetics own 1.8% of the company. Learn More about insider trades at Haemonetics.
Information on this page was last updated on 9/12/2023.

Richard J. Meelia Insider Trading History at Haemonetics

Richard J. Meelia Buying and Selling Activity at Haemonetics

Haemonetics Company Overview

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $87.65

$84.46

$87.76

50 Day Range

MA: $80.03

$71.41

$87.65

2 Week Range

Now: $87.65

$70.74

$95.26

Volume

431,155 shs

Average Volume

448,742 shs

Market Capitalization

$4.45 billion

P/E Ratio

35.63

Dividend Yield

N/A

Beta

0.36

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad